We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04014205
Recruitment Status : Recruiting
First Posted : July 10, 2019
Last Update Posted : September 23, 2022
Sponsor:
Information provided by (Responsible Party):
Beijing InnoCare Pharma Tech Co., Ltd.

Tracking Information
First Submitted Date  ICMJE June 18, 2019
First Posted Date  ICMJE July 10, 2019
Last Update Posted Date September 23, 2022
Actual Study Start Date  ICMJE November 18, 2019
Estimated Primary Completion Date December 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 8, 2021)
  • Part 1 Dose Escalation:The maximum tolerated dose (MTD) [ Time Frame: Incidence of dose limiting toxicities (DLTs) up to 28 days ]
    To determine the maximum tolerated dose (MTD)
  • Part 2 Dose Expansion:ORR [ Time Frame: Up to 2 years ]
    To assess anti-tumor activity of Orelabrutinib (ICP-022) in Patients with B-cell malignancies including r/r MCL, r/r FL, r/r MZL and CLL/SLL with/without prior treatment.
Original Primary Outcome Measures  ICMJE
 (submitted: July 9, 2019)
The maximum tolerated dose (MTD) [ Time Frame: Incidence of dose limiting toxicities (DLTs) up to 28 days ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 25, 2021)
  • Part 1 Dose Escalation:Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability] [ Time Frame: Up to 2 years ]
    The incidence and severity of treatment-emergent AEs will be collected and the safety and tolerability of ICP-022 will be assessed
  • Part 1 Dose Escalation:ORR [ Time Frame: Up to 2 years ]
    Objective response rate
  • Part 1 Dose Escalation:T1/2 [ Time Frame: Up to 2 years ]
    Elimination half-life
  • Part 2 Dose Expansion:Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability] [ Time Frame: Up to 2 years ]
    The incidence and severity of treatment-emergent AEs will be collected and the safety and tolerability of ICP-022 will be assessed
  • Part 2 Dose Expansion:DOR [ Time Frame: Up to 2 years ]
    Duration of response
Original Secondary Outcome Measures  ICMJE
 (submitted: July 9, 2019)
Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability] [ Time Frame: Up to 2 years ]
The incidence and severity of treatment-emergent AEs will be collected and the safety and tolerability of ICP-022 will be assessed
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures
 (submitted: July 9, 2019)
  • Objective response rate (ORR) [ Time Frame: Up to 2 years ]
    ORR of ICP-022 will be assessed by the investigator using standard criteria for Non-Hodgkin's lymphoma [2014 Lugano Classification criteria International working group non-hodgkin's lymphoma (IWGNHL) (Cheson et al., 2014) and the International Workshop on Chronic Lymphocytic Leukemia (IWCLL), (Hallek et al., 2008)]
  • Elimination half-life (T1/2) [ Time Frame: 28 days/cycle, Cycle1 Day 1 and Day 8 pre-dose (-10 minutes), 15 minutes, 30 minutes, 1, 2, 4, 8 and 24 hours (before dosing on next day) after study medication administration; Cycle2 Day1 pre-dose (-10 minutes) ]
  • Total plasma exposure - Area under the concentration time curve (AUC) [ Time Frame: 28 days/cycle, Cycle1 Day 1 and Day 8 pre-dose (-10 minutes), 15 minutes, 30 minutes, 1, 2, 4, 8 and 24 hours (before dosing on next day) after study medication administration; Cycle Day1 pre-dose (-10 minutes) ]
  • Time to reach maximum observed plasma concentration (Tmax) [ Time Frame: 28 days/cycle, Cycle1 Day 1 and Day 8 pre-dose (-10 minutes), 15 minutes, 30 minutes, 1, 2, 4, 8 and 24 hours (before dosing on next day) after study medication administration; Cycle2 Day1 pre-dose (-10 minutes) ]
  • Maximum plasma concentration observed (Cmax) [ Time Frame: 28 days/cycle, Cycle 1 Day 1 and Day 8 pre-dose (-10 minutes), 15 minutes, 30 minutes, 1, 2, 4, 8 and 24 hours (before dosing on next day) after study medication administration; Cycle 2 Day1 pre-dose (-10 minutes) ]
  • Minimum plasma concentration (Cmin) under steady-state conditions within a dosing interval [ Time Frame: 28 days/cycle, Cycle1 Day 1 and Day 8 pre-dose (-10 minutes), 15 minutes, 30 minutes, 1, 2, 4, 8 and 24 hours (before dosing on next day) after study medication administration; Cycle2 Day1 pre-dose (-10 minutes) ]
  • clearance (CL) [ Time Frame: 28 days/cycle, Cycle1 Day 1 and Day 8 pre-dose (-10 minutes), 15 minutes, 30 minutes, 1, 2, 4, 8 and 24 hours (before dosing on next day) after study medication administration; Cycle2 Day1 pre-dose (-10 minutes) ]
  • Volume of distribution at steady-state (Vss) [ Time Frame: 28 days/cycle, Cycle 1 Day 1 and Day 8 pre-dose (-10 minutes), 15 minutes, 30 minutes, 1, 2, 4, 8 and 24 hours (before dosing on next day) after study medication administration; Cycle2 Day1 pre-dose (-10 minutes) ]
 
Descriptive Information
Brief Title  ICMJE A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Official Title  ICMJE A Phase I/II,Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies
Brief Summary This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Part 1:r/r B-cell Malignancies
  • Part 2:B-cell Malignancies
Intervention  ICMJE Drug: Orelabrutinib (ICP-022)
ICP-022 The drug product is a white, round, uncoated tablet
Study Arms  ICMJE
  • Experimental: Part 1 Dose Escalation
    Patients with r/r B-cell malignancies including Grades 1-3a FL, MZL, MCL, and CLL/SLL
    Intervention: Drug: Orelabrutinib (ICP-022)
  • Experimental: Part 2 Dose Expansion

    Arm 1: Patients with r/r MCL

    Arm 2: Patients with other types of B-cell malignancies, including:

    • CLL/SLL with/without prior treatment
    • r/r FL
    • r/r MZL
    Intervention: Drug: Orelabrutinib (ICP-022)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 25, 2021)
81
Original Estimated Enrollment  ICMJE
 (submitted: July 9, 2019)
15
Estimated Study Completion Date  ICMJE November 30, 2024
Estimated Primary Completion Date December 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Signed Informed Consent.
  2. Age ≥ 18 years.
  3. Part 1: Patients with histologically confirmed relapsed or refractory B-cell malignancies, including Grades 1-3a FL, MZL, MCL, and CLL/SLL.

    Part 2: Patients with histologically confirmed B-cell malignancies including r/r FL, r/r MZL and CLL/SLL with/without prior treatment.

  4. Life expectancy (in the opinion of the investigator) of ≥ 4 months.
  5. ECOG performance status of 0 ~1.
  6. Must have adequate organ function.
  7. Negative test results for HBV ([HBsAg (-)] and non-active HBV or HCV infection

Exclusion Criteria:

  1. Pregnant or breast-feeding or intending to become pregnant during the study.
  2. Prior treatment with systemic immunotherapeutic agents.
  3. Known allergies to Orelabrutinib (ICP-022) or its excipients or infection with HIV.
  4. Treatment with any chemotherapeutic agent, or any other investigational therapies within 4 weeks prior to first dose of the study drug.
  5. History of allogeneic stem-cell (or other organ) transplantation or confirmed progressive PML.
  6. Any external beam radiation therapy within 6 weeks prior to the first dose of the study drug.
  7. Concurrent use of warfarin or other vitamin K antagonists or anticoagulation therapies or strong CYP3A inhibitor.
  8. Active uncontrolled infections.
  9. Recent infection requiring IV anti-infective treatment that was completed ≤ 14 days before the first dose of study drug.
  10. Unresolved toxicities from prior anti-cancer therapy.
  11. Medically apparent CNS lymphoma or leptomeningeal disease.
  12. Current or previous history of CNS disease.
  13. Major surgery or significant traumatic injury < 28 days prior to the first dose of the study drug.
  14. Patients with another invasive malignancy in the last 2 years.
  15. Significant cardiovascular disease or active pulmonary disease.
  16. Received systemic immunosuppressive medications.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Olivia Yang +1 (609) 524-0684 ClinicalTrialsInfo@innocarepharma.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04014205
Other Study ID Numbers  ICMJE ICP-CL-00107
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Beijing InnoCare Pharma Tech Co., Ltd.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Beijing InnoCare Pharma Tech Co., Ltd.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Beijing InnoCare Pharma Tech Co., Ltd.
Verification Date September 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP